Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (Q54597304)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. |
scientific article |
Statements
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (English)
Razelle Kurzrock
Stacy Moulder
John Moroney
Thorunn Helgason
Jennifer Wheler
Daniel Booser
Constance Albarracin
Phuong K Morrow
Kimberly Koenig
11 April 2011
29
19
e572-5